EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Comparison of Thiotepa, Busulfan, and Cyclophosphamide Versus Busulfan and Thiotepa Conditioning Regimens in Autologous Stem Cell Transplantation for Primary CNS Lymphoma: A Multicenter Retrospective Analysis

Eun-Jeong Jeong iD, Sang Eun Yoon iD, Sang-A Kim iD, Ji Yun Lee, Seok Jin Kim iD, Soo-Mee Bang iD, Won Seog Kim, Jeong-Ok Lee iD

Hematological Oncology · 2026

DOI: 10.1002/hon.70244 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Hematological Oncology, 2026. Verfasst von Eun-Jeong Jeong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology and Oncology, Gyeongsang National University Hospital, Gyeongsang National University College…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Central Nervous System Neoplasms, Hematopoietic Stem Cell Transplantation, Lymphoma. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autologous stem cell transplantation (ASCT) with thiotepa‐based conditioning has replaced whole‐brain radiotherapy as consolidation for primary central nervous system lymphoma (PCNSL), providing improved efficacy and reduced neurotoxicity. However, the optimal thiotepa‐containing regimen remains undefined. We retrospectively analyzed patients aged ≤ 60 years who underwent ASCT with thiotepa–busulfan–cyclophosphamide (TBC) or busulfan–thiotepa (BuTT) conditioning after high‐dose methotrexate–based induction at two Korean institutions between 2015 and 2023. Propensity score matching (PSM; n = 20 per group) was performed to adjust for baseline differences. Sixty‐seven patients were included (TBC, n = 30; BuTT, n = 37). TBC was associated with significantly longer progression‐free survival (PFS) from induction (3‐year: 89.9% vs. 72.1%, p = 0.034) and from transplantation (89.9% vs. 69.2%, p = 0.032); overall survival did not differ significantly. In multivariable Cox regression adjusted for pre‐transplant response and cumulative MTX exposure, BuTT was independently associated with inferior PFS (HR 4.09, 95% CI 1.27–13.18, p = 0.019). After PSM, TBC retained superior PFS (84.7% vs. 73.3%, p = 0.035), with a non‐significant trend in Cox analysis (HR 0.22, 95% CI 0.05–1.03, p = 0.054). TBC was associated with delayed engraftment and more grade ≥ 3 non‐hematologic toxicities, but no treatment‐related mortality occurred. In younger patients with PCNSL, TBC demonstrated a trend toward more durable disease control than BuTT, with manageable toxicity. As the thiotepa dose represents the major distinction between regimens, dose‐intensified thiotepa strategies with adjusted partner agents merit further prospective investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsHematopoietic Stem Cell TransplantationLymphomaTransplantation ConditioningAdultFemaleHumansMaleMiddle AgedBusulfanCyclophosphamideRetrospective StudiesThiotepaTransplantation, Autologous

Stichwörter der Autor:innen

autologous stem cell transplantationbusulfanconditioning regimenprimary central nervous system lymphomaprogression‐free survivalthiotepa

Substanzen

BusulfanCyclophosphamideThiotepa

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Hematology and Oncology, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, South Korea.
  • Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.

ORCID-Profile: Eun-Jeong Jeong, Sang Eun Yoon, Sang-A Kim, Seok Jin Kim, Soo-Mee Bang, Jeong-Ok Lee

Zitieren

APA

Jeong, E. J., Yoon, S. E., Kim, S. A., Lee, J. Y., Kim, S. J., Bang, S. M., Kim, W. S., & Lee, J. O. (2026). Comparison of Thiotepa, Busulfan, and Cyclophosphamide Versus Busulfan and Thiotepa Conditioning Regimens in Autologous Stem Cell Transplantation for Primary CNS Lymphoma: A Multicenter Retrospective Analysis. Hematological Oncology. https://doi.org/10.1002/hon.70244

Vancouver

Jeong EJ, Yoon SE, Kim SA, Lee JY, Kim SJ, Bang SM, et al. Comparison of Thiotepa, Busulfan, and Cyclophosphamide Versus Busulfan and Thiotepa Conditioning Regimens in Autologous Stem Cell Transplantation for Primary CNS Lymphoma: A Multicenter Retrospective Analysis. Hematological Oncology. 2026. doi:10.1002/hon.70244

BibTeX
@article{Jeong2026,
  author = {Jeong, Eun-Jeong and Yoon, Sang Eun and Kim, Sang-A and Lee, Ji Yun and Kim, Seok Jin and Bang, Soo-Mee and Kim, Won Seog and Lee, Jeong-Ok},
  title = {Comparison of Thiotepa, Busulfan, and Cyclophosphamide Versus Busulfan and Thiotepa Conditioning Regimens in Autologous Stem Cell Transplantation for Primary CNS Lymphoma: A Multicenter Retrospective Analysis},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70244}
}
Kostenlos starten →